Cited by 2,052Hepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus StudiesHead and Neck Cancer Studies

The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Open access

Singal, Amit G., Llovet, Josep M., Yarchoan, Mark, Mehta, Neil, Heimbach, Julie K., Dawson, Laura A., Jou, Janice H., Kulik, Laura M., Agopian, Vatche G., Marrero, Jorge A., Mendiratta-Lala, Mishal, Brown, Daniel B., Rilling, William S., Goyal, Lipika, Wei, Alice C., Taddei, Tamar H.·2023·Hepatology

DOI 10.1097/hep.0000000000000466PMC PMC10663390

Open this paper in CoChat — free account Open PDF

Abstract

Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000466

Cites

338 of 338 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
Influential
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Hepatocellular carcinoma
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citation
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”

Show all 341 references

Research works printed but not linked: 2

Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057

Sorted by citations

Items 901–1,000 of 1,000

Artificial Intelligence in Hepatocellular Carcinoma: Current Applications, Clinical Performance, and Barriers to Implementation
Boppana, S. H., Chandrashekar, A., Maddineni, G., Chakinala, R. C., Raj, R., Shivaprakash, R. B., Yarra, P., Sunkesula, V. C. K., & Mintz, C. D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072484 · Cited by 2
“AASLD recommends ultrasound-based surveillance, typically with AFP, for at-risk patients, and the 2024 US LI-RADS update formalizes visualization scoring to account for suboptimal examinations in obesity, steatosis, and advanced cirrhosis [3,12].”
Influential
Thermal and Nonthermal Liver Ablation: Mechanistic Foundations, Clinical Implementation, Immunologic Trial Design, and Artificial Intelligence
Centner, C. S., Choi, R., Georgiades, C. S., Yarchoan, M. M., & Weiss, C. R. (2026) · Radiology · doi:10.1148/radiol.250263 · Cited by 2
Self-citation
Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicentric Study
Clusmann, J., Koop, P., Zhang, D. Y., van Haag, F., Nahhas, O. S. M. E., Seibel, T., Žigutytė, L., Kaewdech, A., Caldéraro, J., Tacke, F., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1323 · Cited by 6
“Nevertheless, it functions as such in various guidelines (8, 13).”
Influential
Balancing Tumor Response and Rejection Risk After Pre-Transplant Immunotherapy: A Scoping Review
Demirors, B., LIN, M., Spitz, F. J., Abdullah, A., Sethi, V., & Molinari, M. (2026) · Cancers · doi:10.3390/cancers18081284 · Cited by 2
“Guideline recommendations range from 4 to 12 weeks, whereas contemporary observational data suggest that longer intervals (50–94 days) may further mitigate rejection risk [31,33,34].”
An automated and portable magnetically-controlled microfluidic chip platform with dual detection modes for sensitive AFP quantification
Zhang, P., Zhang, C., Jia, M., Pan, Y., Wu, S., Cheng, J., Song, L., & Ming, Z. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345570 · Cited by 2
Biologically Refined Oncological Resectability for Hepatocellular Carcinoma
Aso, K., Takeda, Y., Takahashi, A., Irie, S., Hirata, Y., Ichida, H., Yoshioka, R., Kotera, Y., Mise, Y., & Saiura, A. (2026) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.70119 · Cited by 2
Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma
Zavareh, M. S. R., Ahn, J. C., Kim, H., Luu, M., Ayoub, W. S., Kuo, A., Trivedi, H. D., (32846), Y. W., Vipani, A., Todo, T., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000951 · Cited by 2
Self-citation
Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management
Albusta, N., Isa, S., & Alrahma, H. N. S. (2026) · Diseases · doi:10.3390/diseases14050173 · Cited by 5
“Other agents under investigation include dual GLP-1/glucagon receptor agonists, FGF21 analogs, PPAR agonists, and combination strategies targeting complementary metabolic, inflammatory, and fibrotic pathways [81].”
Influential
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort
Moon, A. M., Yanagihara, T. K., Dawson, L. A., Yu, J. I., Lawrence, T. S., Kim, T. S., Yan, M., Iwata, H., Nabavizadeh, N., Apisarnthanarax, S., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02399 · Cited by 2
Self-citation
Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child–Turcotte–Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression
Agrawal, D., Jothimani, D. K., Bhoori, S., Reddy, G. N., Saigal, S., Rela, M., & Mazzaferro, V. (2026) · Hepatology International · doi:10.1007/s12072-026-11097-1 · Cited by 2
“The timing and sequence of LRT and ICI combination regimens vary across clinical practice [72].”
Modular CRISPR−Cas12a-Activated Gold Nanoparticle Assay for Rapid Visual Detection of Hepatocellular Carcinoma-Related miRNAs
Sun, Y., Wang, R., Sun, H., Chen, J. Y., Liang, C., Zhang, Z., Feng, Y., Chen, L., & Wang, X. (2026) · ACS Sensors · doi:10.1021/acssensors.6c00916 · Cited by 2
Large Language Models for Multidisciplinary Tumor Board Decision-Making in Primary Liver Tumors: A Retrospective Single-Center Study
Palzer, J., Genchev, A., Belger, E., Weigle, C. A., Wiemann, B. A., Tessmer, P., Murad, M., Berres, M., Meister, F., Amygdalos, I., et al. (2026) · Cancers · doi:10.3390/cancers18132175 · Cited by 2
“Available treatment modalities range from curative approaches such as surgical resection, liver transplantation, and local ablation to transarterial therapies, stereotactic body radiotherapy (SBRT), and systemic treatment with targeted agents and immune check-point inhibitors [13,14].”
Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy
Chon, Y. E., Han, K., Yang, J. D., Park, J., Kim, H.-S., Lee, H. W., Lim, T. S., & Kim, B. K. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70635 · Cited by 2
The Effect of Cooling Fluid Composition on Ablation Size in Hepatic Laser Ablation: A Comparative Study in an Ex Vivo Bovine Setting
Mankertz, F., Bayerl, N., Gemeinhardt, O., Hosten, N., & Kromrey, M. (2023) · Tomography · doi:10.3390/tomography9050131 · Cited by 2
“According to the Barcelona Clinic Liver Cancer’s staging system, hyperthermic treatment through radiofrequency ablation (RFA) and microwave ablation (MWA) can be considered equivalent to surgical hepatectomy in certain cases [1].”
BackgroundInfluential
Predicting Outcome after Percutaneous Ablation for Early-Stage Hepatocellular Carcinoma Using Various Imaging Modalities
Shimizu, R., Ida, Y., & Kitano, M. (2023) · Diagnostics · doi:10.3390/diagnostics13193058 · Cited by 2
Quantitative diffusion weighted imaging in patients with hepatocellular carcinoma: effects of simultaneous multi-slice acceleration and gadoxetic acid administration
Yang, T., Ye, Z., Yao, S., Wu, Y., Yin, T., & Song, B. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04100-y · Cited by 2
Contrast-Enhanced Ultrasound With Perfluorobutane for Hepatocellular Carcinoma Diagnosis: Comparison of Imaging Phases and Diagnostic Criteria
Kang, H., Lee, J. M., Yoon, J. H., Yoo, J., Kim, J. H., & Park, J. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.23.30156 · Cited by 2
Hepatocellular Carcinoma from a Hepatologist's Perspective
Roldan, G. A., Blomker, J., & Aby, E. S. (2023) · Seminars in Interventional Radiology · doi:10.1055/s-0043-1777846 · Cited by 2
“12,17,18 Multiple international organizations, including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of Liver (EASL), and the Asian Paci ﬁ c Association for the Study of the Liver (APASL), recommend surveillance of patients with increased…”
BackgroundInfluential
Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma
Lang, D., Agarwal, R., Brown, S. A., Borgmann, A. J., Lockney, N. A., Goff, L. W., & Heumann, T. R. (2024) · Advances in Oncology · doi:10.1016/j.yao.2024.02.002 · Cited by 2
Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
Hou, C., Xiong, B., Zhou, L., Fei, Y., Shi, C., Zhu, X., Xie, T., & Wu, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12144-6 · Cited by 2
Characterization of Microwave Generator Energy and Ablation Volumes following Transarterial Embolization in an In Vivo Porcine Liver Model
Sparks, H. D., Rink, J. S., Ramakrishnan, A., Sung, K., Ni, J., Lu, D. S. K., Raman, S. S., Lee, E. W., & Chiang, J. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.05.005 · Cited by 2
An Investigative Analysis of Therapeutic Strategies in Hepatocellular Carcinoma: A Raetrospective Examination of 23 Biopsy-Confirmed Cases Emphasizing the Significance of Histopathological Insights
Grasu, M. C., Dumitru, R. L., Zgura, A. F., Toma, L., Iliescu, L. E., & Baciu, C. C. (2024) · Cancers · doi:10.3390/cancers16101916 · Cited by 1
Abdominal Wall Needle Tract Seeding: 15 Years After a Hepatocellular Carcinoma Biopsy
Saldanha, G., Antunes, S. C., Cruz, J., & Ramalho, M. (2024) · Cureus · doi:10.7759/cureus.61131 · Cited by 2
“Despite the implementation of dedicated viral hepatitis elimination programs, chronic infections with hepatitis B virus and hepatitis C virus remain the predominant etiologic risk factors in many regions [2].”
Background
Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: A claims database analysis
Cheng, S., Bansal, A., & Veenstra, D. L. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.6.572 · Cited by 2
Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis
Li, Y., Liu, X., Liu, J., Yang, L., Wei, S., Li, J.-J., Gan, H., Ma, T., & Yi, P. (2024) · Oncology Letters · doi:10.3892/ol.2024.14480 · Cited by 2
“Transarterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors are widely recommended for the treatment of intermediate to advanced HCC (6,7).”
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study
Zhang, Y., Numata, K., Imajo, K., Uojima, H., Funaoka, A., Komiyama, S., Ogushi, K., Chuma, M., Irie, K., Kokubu, S., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14089 · Cited by 3
Prognostic Factors of Pulmonary Metastasectomy for Oligometastatic Hepatocellular Carcinoma Spread to the Lungs
Kim, B., Moon, M. H., & Moon, S. W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144241 · Cited by 2
Tamoxifen for adults with hepatocellular carcinoma
Naing, C. M., Ni, H., & Aung, H. H. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014869.pub2 · Cited by 1
Chronobiology of Cancers in the Liver and Gut
Ferrell, J. M. (2024) · Cancers · doi:10.3390/cancers16172925 · Cited by 3
“HCC often requires multidisciplinary care and surgical resection is the most common and preferred treatment, followed by systemic therapies reserved for patients with non-resectable HCC [82].”
Background
Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study
Uekusa, S., Nemoto, M., Hanai, Y., Nakashin, M., Yanagino, S., Arita, Y., Μatsumoto, T., Wakui, N., Nagai, H., Higai, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70065 · Cited by 2
Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
den Toom, W., Negenman, E. M., Willemssen, F. E. J. A., van Werkhoven, E. D., Porte, R. J., de Wilde, R. F., Sprengers, D., Antonisse, I. E., Heijmen, B. J. M., & Romero, A. M. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100878 · Cited by 2
“Surgical resection or liver transplantation are considered the first choice of treatment for patients with limited disease [3 – 5].”
Background
Results of hepatocellular carcinoma downstaging through hepatic transarterial chemoembolization in liver transplantation
de Morais, B. G., Horbe, A. F., Coral, G. P., Jotz, R. D. F., Fontana, P. C., & de Mattos, Â. A. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002869 · Cited by 2
Systemic Therapy for Hepatocellular Carcinoma
Kinsey, E. N., & Morse, M. A. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.010 · Cited by 4
New strategy of LI-RADS v2018 to improve the sensitivity for small hepatocellular carcinoma ≤ 3.0 cm on extracellular-contrast enhanced MRI
Zhou, J., Zhang, Y., Zhang, J., Chen, J., Jiang, H., Zhang, L., Zhong, X. Z., Zhang, T., Chen, L., Wang, Y., et al. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111830 · Cited by 2
Risk factors for lenvatinib‐induced hypertension in patients with hepatocellular carcinoma: A retrospective study
Uekusa, S., Nakashin, M., Hanai, Y., Nemoto, M., Yanagino, S., Arita, Y., Μatsumoto, T., Wakui, N., Nagai, H., Higai, K., et al. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16337 · Cited by 2
Performing liver imaging at a high level: quality and adequacy in LI-RADS
Hong, C. W., Cunha, G. M., Yokoo, T., Roudenko, A., Kelm, Z. S., Fung, A., Bashir, M. R., Lewis, S. C., Santillan, C., Marks, R. M., et al. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04679-w · Cited by 2
“Hepatocellular carcinoma (HCC) continues to be a leading cause of cancer-related death worldwide despite advances in healthcare [1].”
An open-label, randomized, controlled trial on the benefit of β-hydroxy-β-methyl butyrate, l-arginine, l-glutamine combination beverages and locomotion training as supportive care for the treatment of unresectable hepatocellular carcinoma using lenvatinib: A pilot study (HELLO study)
Naganuma, A., Makita, F., Sugimoto, R., Kikuchi, M., Furuta, K., Iwamoto, S., Sakamori, R., Kouno, H., Ario, K., & Yatsuhashi, H. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.12.005 · Cited by 2
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
Wei, M., Zhang, P., Yang, C. F., & Li, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1500496 · Cited by 2
CT perfusion and MRI: A combined approach for hepatocellular carcinoma diagnosis and follow-up after locoregional treatment
Kalarakis, G., Chryssou, E. G., Perisinakis, K., Klontzas, M. E., Samonakis, D. N., & Hatzidakis, A. A. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.111928 · Cited by 2
Safety and recommendation of voriconazole for invasive pulmonary aspergillosis in severe liver disease patients: a retrospective cohort study
Zhang, X., Zheng, C., Zhang, L., Sun, Y., Liang, Y., Chen, X., Pang, L., & Zhang, Y. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10459-8 · Cited by 2
Serum PKCδ is a useful biomarker to distinguish hepatocellular carcinoma from other gastrointestinal cancers
Ueda, K., Oikawa, T., Yamada, K., Tsubota, A., Saeki, C., Katagiri, K., Tago, N., Matsumoto, A., Mikuni, H., Ishikawa, M., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151431 · Cited by 2
Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma
Kim, D. H., Choi, S. H., Koo, B., Choi, S. J., Jang, H. J., Heo, S., Byun, J. H., Won, H. J., & Shin, Y. M. (2025) · European Radiology · doi:10.1007/s00330-025-11418-2 · Cited by 2
Automated hepatocellular carcinoma detection and segmentation in abbreviated MRI using vision transformers
Yadav, V., Geahchan, A., Fauveau, V., Yasokawa, K., Taouli, B. A., & Greenspan, H. K. (2025) · SPIE Medical Imaging: Computer-Aided Diagnosis · doi:10.1117/12.3047021 · Cited by 2
Effect of Narrow-Margin Hepatectomy Combined with Intraoperative Radiotherapy on Long-Term Prognosis of Patients with Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Tao, C., Liu, L., Hu, N., Wang, H., Zhang, K., Liu, Y., Wu, F., Wang, L., Rong, W., & Wu, J. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s497998 · Cited by 2
Autologous Tumor-Infiltrating Lymphocyte Infusion plus Anti-Programmed Cell Death Protein 1 Therapy to Cure Advanced Hepatocellular Carcinoma following Palliative Hepatectomy
Xia, T., Yuan, T., Chen, L., Wang, C., Zhang, E., Liang, B.-Y., Zhang, Z., Wang, M.-W., Chen, X., & Huang, Z.-Y. (2025) · Liver Cancer · doi:10.1159/000544163 · Cited by 2
Comparative Radiologic Response Assessment after Transarterial Chemoembolization, Percutaneous Ablation, and Multimodal Treatment: Radiologic-Pathologic Correlation in 81 Tumors
Badar, W., Cooper, E. G., Florido, C., Rabaza, M., Sheikh, U., Guzman, G., & Gaba, R. C. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.02.016 · Cited by 2
Role of Liver Transplant in Primary and Secondary Liver Malignancies
Melehy, A., & Agopian, V. G. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.12.003 · Cited by 2
Self-citation
Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients
Li, Y. H., Li, S., Li, Q., Li, K., Han, J., Mao, S., Xu, X., Su, Z., Zuo, Y., Xie, S., et al. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0980 · Cited by 2
“Contrast-enhanced CT/MRI is globally recognized as the first-line imaging modality for diagnosing HCC [3-6].”
National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma
Roberts, S. K., Majeed, A., Rasaratnam, K., Olynyk, J. K., Shackel, N. A., Wood, M. J., Strasser, S. I., & Wigg, A. J. (2025) · Cancer Medicine · doi:10.1002/cam4.70722 · Cited by 2
Identifying key predictors of mortality and liver decompensation in hepatocellular carcinoma patients treated with transarterial radioembolization
Arabi, M., Alghamdi, H. S., Almesned, A. A., Alanazi, O. I., Alzahrani, K., Alghamdi, M. A., Bukhaytan, M., Alkhalaf, M. F., Almaimoni, M. A., Alagrafy, N. A., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_343_24 · Cited by 2
“[3] In patients with no evidence of cirrhosis, histological confirmation of HCC was required.”
A systematic review and meta-analysis of the comparison of laparoscopic radiofrequency ablation to percutaneous radiofrequency ablation for hepatocellular carcinoma
Wang, Y., Tan, Z.-K., Peng, Z., & Huang, H. Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1559343 · Cited by 2
Identification of candidates with hepatocellular carcinoma to receive TACE combined with MWA by assessing tumor burden and radiologic features
An, C., Shen, L., Chen, Q., Jiang, Y., Li, C., Ren, H., Wu, P., & Liu, X. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251324052 · Cited by 2
The role of contrast-enhanced ultrasound in the radiological classification of liver observations identified by CT and MRI
Huang, H., He, D., Lu, R.-F., Tong, W., Wang, Y., Qin, S., Wen, R., Wu, S.-H., Ruan, S., Liu, G., et al. (2025) · La radiologia medica · doi:10.1007/s11547-025-01995-z · Cited by 2
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
Lee, H. A., Lee, H. W., Seo, Y. S., Sinn, D. H., Ahn, S. H., Kim, B. K., & Kim, S. U. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16973 · Cited by 2
Nivolumab plus ipilimumab in hepatocellular carcinoma
Vithayathil, M. K., & Sharma, R. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00417-9 · Cited by 2
Liver resection versus interventional treatments for hepatocellular carcinoma patients with hypohepatia: a multicenter study
Zhao, S., Zhu, Y., Zhu, J., Wang, B., Wang, E., Zhu, J. W., Wen, L., Zhao, Y., Yang, M. G., Zuo, L., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11785-3 · Cited by 2
Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Diagnosis— AJR Expert Panel Narrative Review
Li, L., Burgio, M. D., Fetzer, D. T., Ferraioli, G., Lyshchik, A. P., Meloni, M. F., Rafailidis, V. D., Sidhu, P. S., Vilgrain, V., Wilson, S. R., et al. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.32813 · Cited by 2
Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study
Chen, Q., Jiang, X., Hu, Y., Chen, S., Lyu, N., & Zhao, M. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095508 · Cited by 2
MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma
Yoon, J. K., & Choi, J. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2025.0029 · Cited by 2
Surveillance for hepatocellular carcinoma in the UK: a root cause analysis towards delivering future improvements
Innes, H. A., Cross, T., Johnson, P. J., Calder, D., & Bird, T. G. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103098 · Cited by 2
“22 Clinical guidelines from Europe and America both now recommend RBS, 6 23 the former arguing that it is a ‘superior strategy to reduce HCC mortality’.”
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
Matono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Liver International · doi:10.1111/liv.70217 · Cited by 2
Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors
Geissler, P., Spautz, S., Hering, K., Seiler, I., Heinicke, F., Sachpazidis, I., Baltas, D., Schäfer, S., Moustakis, C., Nicolay, N. H., et al. (2025) · Physics and Imaging in Radiation Oncology · doi:10.1016/j.phro.2025.100811 · Cited by 2
“…colorectal carcinoma, and both SBRT and HDR-iBT as treatment options for recurrent HCC [18,47], The American Association for the Study of Liver Diseases (AASLD) also recommends liver SBRT as a treatment option for HCC, achieving durable local control in patients unsuitable for resection [48].”
Efficiency and Safety of HAIC Combined with Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma with Lung Metastasis: A Multicenter Propensity Score Matching Analysis
Chen, S., Wang, N., Xiao, Y., Jiang, X., Shi, F., Cai, H., Tang, S., Guo, W., & Zhuang, W. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s542811 · Cited by 2
“9 Although systemic therapy is the mainstay for advanced HCC with extrahepatic spread, intrahepatic tumor burden is the leading cause of death, as most patients succumb to progression of intrahepatic lesions rather than metastatic complications.”
Identifying the Optimal Treatment for Patients with Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Multicenter Propensity Score-Weighted Analysis
Zhao, S.-J., Zhu, J.-M., Zhu, Y.-J., Jia, J., Ren, W.-R., Wang, E., Zhu, J.-L., Zuo, L., Wen, L.-Z., Chen, X., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18744-1 · Cited by 2
“Clinical practice guidelines, 2,24 along with findings from previous studies, 14,15,32 have suggested that ablation should be regarded as the primary treatment strategy for select patients with HCC. Specifically, this recommendation applies when patients present with fewer than three tumors, each…”
Comparable 5‐Year Survival in People With and Without HIV Following Hepatocellular Carcinoma Diagnosis: A Multicenter Study
Iavarone, M. A., Alimenti, E., Puoti, M., Hasson, H., Monti, B., Bhoori, S., Peracchi, F., Siribelli, A., Fava, M., Bruccoleri, M., et al. (2025) · Liver International · doi:10.1111/liv.70437 · Cited by 2
“Eligibility required documented HIV serology (anti-HIV antibodies) and a histological or clinical first diagnosis of HCC per international guidelines [26, 27].”
Arterial-Washout Temporal Profiling in CEUS LI-RADS: A Diagnostic Algorithm for Reducing Hepatocellular Carcinoma Misclassification
Wang, Y., Zhixian, Z., Zhu, M., & Wu, S. (2025) · Radiology Imaging Cancer · doi:10.1148/rycan.250259 · Cited by 2
INASL Consensus on Management of HCC: Navigating an Evolving Field
Singal, A. G., Pillai, A. A., & Parikh, N. D. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.10.003 · Cited by 2
Self-citation
Refining MRI-based criteria for portal vein invasion in hepatocellular carcinoma: improving sensitivity beyond portal vein tumor thrombosis
Kim, J.-A., Jeong, W. K., Kim, J. M., Ha, S. Y., & Kim, K. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04106-6 · Cited by 2
Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion
Chang, C.-J., Hsu, W., Jeng, L., Lai, H., Hsu, S.-C., Chen, T.-H., Wang, H., & Peng, C. (2023) · Current Oncology · doi:10.3390/curroncol30120737 · Cited by 2
“The AASLD and EASL mentioned that surgical resection could only be considered for HCC patients with Vp 1 or 2 MVI in high-volume centers or research settings [4,5].”
BackgroundMethodInfluential
Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab
Ledenko, M., Mercado, L. A., & Patel, T. C. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001067 · Cited by 2
Development and Validation of a Nomogram to Predict the Recurrence of HCC Patients Undergoing CECT After Ablation
Qiao, W., Fan, Z., Wang, Q., Jin, R., & Hu, C. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s441540 · Cited by 2
“17 Due to the retrospective nature of this study, the requirement for informed consent was waived.”
Cancer Prevention and Screening for People Living with Human Immunodeficiency Virus
Wilkinson, M. R., McCrea, K. L., & Culbertson, A. (2024) · Nursing Clinics of North America · doi:10.1016/j.cnur.2024.01.002 · Cited by 2
Liver transplant versus liver resection in patients with multifocal hepatocellular carcinoma
Kakish, H. H., Suraju, M. O., Seth, A., DiGioia, O. N., Pawar, O., Kwon, Y., Hemming, A. W., & Aziz, H. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.04.021 · Cited by 2
Comparison of Characteristics and Survival of New-Onset Hepatocellular Carcinomas With or Without Cirrhosis in a Tertiary Center
Araz, F., Soydaş, B., Özer, B., Karadeli, E., & Erbay, G. (2024) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2024.23451 · Cited by 2
Hepatocellular carcinoma
Chrysavgis, L., & Cholongitas, Ε. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21938-2.00020-5 · Cited by 3
Reply
Singal, A. G., Daher, D., Dahan, K. S. E., Rich, N. E., Yang, J. D., & Parikh, N. D. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.10.032 · Cited by 2
Self-citation
Against multidisciplinarity: More is not necessarily better
Colli, A., & Prati, D. (2024) · Liver International · doi:10.1111/liv.15898 · Cited by 2
Editorial: PIVKA‐II Facilitates Risk Stratification for HCC Following HCV Cure
Su, T., & Liao, W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18444 · Cited by 2
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score?: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease”
Ko, M. K.-L., & Mak, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0118 · Cited by 2
“[ 3] Based on cost-effectiveness analyses, HCC surveillance should be performed in individuals with HCC risk exceeding 1.0 – 1.5% per year.”
Influential
Letter to the Editor: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?
Zhao, Z., Sun, J., You, Q., Lan, Z., & Zhu, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001481 · Cited by 2
Letter to the editor regarding: Lai, Jimmy Che-To, et al "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease"
Gao, W., & Liu, C. (2026) · Gut · doi:10.1136/gutjnl-2026-339053 · Cited by 2
How Systematic Review Can Shape Clinical Practice in Radiology
Kim, T., & Woo, S. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.23.29603 · Cited by 1
Integrating the new systemic treatment landscape and surgical therapy in hepatocellular carcinoma
Haber, P. K., Krenzien, F., Sarıbeyoğlu, K., Pratschke, J., & Schöning, W. (2024) · Turkish Journal of Surgery · doi:10.47717/turkjsurg.2024.6375 · Cited by 1
Optimizing care of HBV infection and HBV-related HCC
Lee, S. Y., Nah, B. K. Y., Leo, J., Koh, J. H., & Huang, D. Q. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000169 · Cited by 1
“[32] The AASLD recommends surveillance with ultrasound examination and alpha-fetoprotein (AFP) every 6 months in people at risk of HCC. [33] In patients with CHB with cirrhosis, both AASLD and EASL recommend surveillance in patients with Childs-Pugh stages A or B and in patients with Childs-Pugh C…”
Die moderne TARE 2023 – von der Palliativversorgung zur kurativen Behandlungsalternative
Gebauer, B., Collettini, F., Pfob, C. H., & Lapa, C. (2024) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-2353-5819 · Cited by 1
“…und Behand-lung des HCC [4], der Leitlinie der Europäischen Arbeitsgemein-schaft zum Studium der Leber (EASL) zum Management des HCC [8] und der Leitlinie zur Behandlung des hepatozellulären Karzinoms der Amerikanischen Gesellschaft für die Erforschung von Leberkrankheiten (AASLD) [11] empfohlen.”
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents
Amadeo, E., Foti, S., Camera, S., Rossari, F., Persano, M., Prinzi, F. L., Vitiello, F., Gardini, A. C., & Rimini, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377321 · Cited by 1
“Particularly important in the field was the advancement of immune checkpoints inhibitors (ICI) application, currently used in first-line regimes [7], over Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the RAF/ MEK/ERK pathway [8].”
Conversion therapy for hepatocellular carcinoma to improve treatment strategies for intermediate and advanced stages
Giorgio, A., & Luca, M. D. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i28.6241 · Cited by 1
Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic hepatitis C virus infection
Cao, J. J., Shon, A., Yoon, L. S., Kamaya, A., & Tse, J. R. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04589-x · Cited by 1
The Role of Liver Transplantation in Hepatocellular Carcinoma
Jakhete, N., Majeed, N. A., Maluf, D. G., & Shetty, K. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.009 · Cited by 1
Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide
Protopapas, A. A., Tsankof, A., Papagiouvanni, I., Kaiafa, G. D., Skoura, L., Savopoulos, C. G., & Goulis, I. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i12.1377 · Cited by 1
A Call for Quality Assurance in Alpha-Fetoprotein Testing within the National Cancer Screening Program to Improve Hepatocellular Carcinoma Surveillance in Korea
Kim, H., Kim, S., Kim, H., & Lee, H. R. (2024) · Laboratory Medicine Online · doi:10.47429/lmo.2025.15.1.84 · Cited by 1
Comparing immunotherapy effectiveness for unresectable hepatocellular carcinoma: infiltrative versus non-infiltrative types in real-world settings
Chiang, C., Huang, K.-K., Lee, C., Hong, T., Wu, J.-S., Wu, H., Chang, T., Liu, Y., Chen, W.-T., Wang, C., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312141 · Cited by 1
“4,5 Moreover, nivolumab demonstrates similar efficacy and safety as a first-line therapy when compared to sorafenib.”
3D synergistic tumor-liver analysis further improves the efficacy prediction in hepatocellular carcinoma: a multi-center study
Jiang, Y., Zhang, J., Liu, Z., Zhang, J., Yu, X., Lin, D., Dong, D., Cai, M., Duan, C., Liu, S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13501-9 · Cited by 1
“Initial treatment included liver resection or TACE, a decision made by a multidisciplinary team relying on established guidelines [3, 4, 15, 16], considering tumor characteristics, liver function, and patients’ treatment intention.”
Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC
Zheng, T., Sheng, L., Wu, Y., Zhu, X., Yang, Y., Zhang, X., Bashir, M. R., Ronot, M., Sun, H., Wang, Y., et al. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.111945 · Cited by 1
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC
Matono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16884 · Cited by 1
Evaluation of screening program for hepatocellular carcinoma at a single center
El-Azab, G., El-Helw, G. A. A., Elsabaawy, M., Kohla, M., & Omar, Y. A. M. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00404-4 · Cited by 2
Oligometastatic Hepatocellular Carcinoma to the Perirectal Pelvis, a Rare Site of Distant Spread
Lupu, G. V., Barritt, A. S., Iuga, A. C., Moon, A. M., Sanoff, H. K., Yanagihara, T. K., & Gangarosa, L. M. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001615 · Cited by 1
Nomogram for Predicting Severe Abdominal Pain During Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Study
Tian, J.-M., Zhang, J., Liu, H., Wang, F., Yang, Q.-S., Luo, R., & Yang, J.-J. (2025) · Journal of Pain Research · doi:10.2147/jpr.s506099 · Cited by 1
Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma
Kim, H., Park, Y.-G., Hong, H., Chung, S. W., Kim, S., Ryu, M., Ryoo, B., Choi, J., Lee, D., Shim, J. H., et al. (2025) · Oncology · doi:10.1159/000545351 · Cited by 1
“However, sorafenib and len-vatinib, previous the ﬁ rst-line therapy options, remain viable if patients are ineligible for atezolizumab-bevacizumab and the STRIDE regimens [7, 8].”
Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis
Chun, S. J., Yoo, J., Kim, S. G., & Kim, Y. S. (2025) · Diagnostics · doi:10.3390/diagnostics15070818 · Cited by 1
“Patients without cirrhosis, or those with HCC arising from fatty liver, are less likely to display typical imaging features, complicating diagnosis [1,9].”

Authors: Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
Affiliations: The University of Texas Southwestern Medical Center (US)
Institució Catalana de Recerca i Estudis Avançats (ES)
Johns Hopkins University (US)
University of California, San Francisco (US)
Mayo Clinic (US)
University Health Network (CA)
Oregon Health & Science University (US)
Northwestern Medical Faculty Foundation (US)
University of California, Los Angeles (US)
University of Pennsylvania (US)
Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Vanderbilt University Medical Center (US)
Medical College of Wisconsin (US)
Stanford Medicine (US)
Memorial Sloan Kettering Cancer Center (US)
Yale University (US)
Corresponding author: Singal, Amit G.
ORCID: Singal, Amit G.
Llovet, Josep M.
Yarchoan, Mark
Mehta, Neil
Heimbach, Julie K.
Dawson, Laura A.
Jou, Janice H.
Kulik, Laura M.
Agopian, Vatche G.
Marrero, Jorge A.
Brown, Daniel B.
Goyal, Lipika
Wei, Alice C.
Taddei, Tamar H.
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2023-05-22
Volume: 78
Issue: 6
Pages: 1922-1965
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1097/hep.0000000000000466
PMC: PMC10663390
OpenAlex: W4377011124
Cited by: 2,052
References: 341
Citations by year: 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
FWCI: 346.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
American Association for the Study of Liver Diseases
Gilead Sciences
Boston Scientific Corporation
Exelixis
Incyte
Cancer Research UK (26813)
Eisai
Ipsen
Sirtex Medical
National Institutes of Health (UL1TR001863)
Genentech
National Cancer Institute (P50CA062924, R01CA285544)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords: hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
MeSH terms: Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks